Options for radionuclide therapy: from fixed activity to patient-specific treatment planning

Cancer Biotherapy & Radiopharmaceuticals
Stephen R Thomas

Abstract

The therapeutic use of radioisotopes in medicine as unsealed sources has a long history dating back to the 1930s. The established and continuing objectives are to provide radiation dose to the target tissue at the desired cytotoxic level while avoiding or minimizing toxic effects. Selected radionuclide therapy protocols including 32P for polycythemia vera, 131I for Graves' disease, and 131I for postsurgical ablation of thyroid remnants in the management of differentiated thyroid cancer are presented for historical review with the focus on protocols for administering the radiopharmaceuticals and the role played by dosimetry. The discussion also includes consideration of complications and the assessment of outcome for these diseases. The vista for radionuclide therapy today is reviewed along with the options for determining the administered activity. Patient specific dosimetry encompasses a number of levels ranging from basic measurement of relevant biokinetic parameters and use of standard models to calculate (and extrapolate) radiation dose to sophisticated three-dimensional techniques employing fusion of physiologic and high-resolution anatomic images coupled with advanced 3-D voxel patient representation and Monte Carlo techn...Continue Reading

References

Feb 1, 1976·The British Journal of Radiology·F W SpiersS D King
Jan 1, 1991·European Journal of Nuclear Medicine·S E Clarke
Jan 1, 1991·European Journal of Nuclear Medicine·C A Hoefnagel
Aug 1, 1990·The Journal of Clinical Endocrinology and Metabolism·L J DeGrootF H Straus
May 1, 1972·The British Journal of Radiology·J M HenkG M Owen
Sep 16, 1968·JAMA : the Journal of the American Medical Association·E L SaengerE A Tompkins
Oct 20, 1983·The New England Journal of Medicine·H R MaxonE L Saenger
Jun 1, 1983·The Journal of Clinical Endocrinology and Metabolism·N A SamaanC E Litton
Nov 1, 1995·Health Physics·P J Early, E R Landa
Nov 1, 1994·The American Journal of Medicine·E L Mazzaferri, S M Jhiang
Sep 1, 1996·Medical Physics·E E FurhangG Sgouros
Nov 14, 1997·The Journal of Laboratory and Clinical Medicine·N I Berlin, L R Wasserman
Aug 1, 1998·JAMA : the Journal of the American Medical Association·E RonJ D Boice
Sep 18, 1999·Lancet·J F Chatal, C A Hoefnagel
Mar 23, 2000·Seminars in Radiation Oncology·S J Knox, R F Meredith
Mar 23, 2000·Seminars in Radiation Oncology·I R McDougall
Jun 22, 2001·Critical Reviews in Oncology/hematology·G L DeNardoS J DeNardo
May 1, 1963·The British Journal of Radiology·A W GOOLDEN, J B DAVEY
Jul 9, 1964·The New England Journal of Medicine·R A SELTZERE L SAENGER
Oct 1, 1951·The Journal of Clinical Endocrinology and Metabolism·R W RAWSONW PEACOCK

❮ Previous
Next ❯

Citations

Jun 14, 2003·Cancer Biotherapy & Radiopharmaceuticals·Gerald DeNardoSally DeNardo
Sep 30, 2004·Cancer Biotherapy & Radiopharmaceuticals·Thomas KullGerhard Glatting
Jul 3, 2008·Cancer Biotherapy & Radiopharmaceuticals·Michael G Stabin
Aug 26, 2010·Cancer Biotherapy & Radiopharmaceuticals·Joseph J GrudzinskiRobert Jeraj
Feb 23, 2013·Clinical Nuclear Medicine·José WillegaignonCarlos Alberto Buchpiguel
Feb 8, 2013·Medical Physics·José WillegaignonCarlos A Buchpiguel
Oct 14, 2011·Medical Physics·Ali-Asghar ParachMohammad-Ali Askari
Apr 20, 2013·Zeitschrift für medizinische Physik·Gerhard GlattingMichael Lassmann
Oct 6, 2009·Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)·Antonio C TrainoGiuliano Mariani
Nov 3, 2009·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·J J GrudzinskiJ P Weichert
Nov 19, 2015·European Journal of Nuclear Medicine and Molecular Imaging·Deni HardiansyahGerhard Glatting
Mar 31, 2015·Radiation Protection Dosimetry·Sören Mattsson
Mar 31, 2005·Physics in Medicine and Biology·Joerg LehmannGerald Denardo
Jun 9, 2005·Nuclear Medicine Communications·Klaus Bacher, Hubert M Thierens
Jun 9, 2005·Nuclear Medicine Communications·Hubert M ThierensKlaus Bacher

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Cancer Biotherapy & Radiopharmaceuticals
Christine L Hartmann SiantarS J DeNardo
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)
A C TrainoGiuliano Mariani
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Michael G StabinJeffry A Siegel
© 2022 Meta ULC. All rights reserved